MapLight’s Jonathan Gillis proposes $2.08M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. officer Jonathan Gillis gave notice of a proposed sale of 69,835 common shares, with an approximate sale date of April 27, 2026 and an aggregate market value of $2,078,289.60. The notice lists December 26, 2025 as the Rule 10b5-1 plan adoption or instruction date.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Units financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.